{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:03:30Z","timestamp":1784721810987,"version":"3.55.0"},"reference-count":77,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14760584.2026.2704173","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:26:18Z","timestamp":1784719578000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Quantifying the societal benefits of adult immunization against respiratory diseases in France: a benefit cost analysis"],"prefix":"10.1080","volume":"25","author":[{"given":"Matthew","family":"Napier","sequence":"first","affiliation":[{"name":"Office of Health Economics","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Brassel","sequence":"additional","affiliation":[{"name":"Office of Health Economics","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Tunnicliffe","sequence":"additional","affiliation":[{"name":"Office of Health Economics","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claud","family":"Theakston","sequence":"additional","affiliation":[{"name":"Office of Health Economics","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Fievez","sequence":"additional","affiliation":[{"name":"Pfizer SAS","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Fahfouhi","sequence":"additional","affiliation":[{"name":"Pfizer SAS","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoub","family":"Boukhlal","sequence":"additional","affiliation":[{"name":"Pfizer SAS","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7750","authenticated-orcid":false,"given":"Elisabeth","family":"Botelho-Nevers","sequence":"additional","affiliation":[{"name":"University Hospital of Saint-Etienne","place":["Saint-Etienne, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Guerin","sequence":"additional","affiliation":[{"name":"University Hospital of Nice, UNiCA","place":["Nice, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Vietri","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mendes","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Tadworth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyan","family":"Hu","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Steuten","sequence":"additional","affiliation":[{"name":"Office of Health Economics","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"Institut national d\u2019\u00e9tudes d\u00e9mographiques. Population aging is accelerating in France and most developed countries | INED [Internet]. 2021 [cited 2026 Mar 18]. Available from: https:\/\/www.ined.fr\/en\/all-about-population\/focus\/population-aging-accelerating-france-and-most-developed-countries"},{"key":"e_1_3_6_3_1","unstructured":"Inserm Fondation. Increase in chronic diseases [Internet]. Inserm Fondation; 2026 [cited 2026 Mar 18]. Available from: https:\/\/fondation-inserm.org\/en\/our-areas-of-action\/meeting-major-societal-challenges\/increase-in-chronic-diseases\/"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12962"},{"key":"e_1_3_6_5_1","unstructured":"Sant\u00e9 publique France. G\u00e9odes - Sant\u00e9 publique France [Internet]. 2025 [cited 2025 Oct 3]. Available from: https:\/\/geodes.santepubliquefrance.fr\/#c=home"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf735"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2024-001836"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae349"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2515760"},{"key":"e_1_3_6_10_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Strat\u00e9gie vaccinale de pr\u00e9vention des infections par le VRS chez l\u2019adulte \u00e2g\u00e9 de 60 ans et plus [Internet]. Haute Autorit\u00e9 de Sant\u00e9; 2024 [cited 2026 Feb 17]. Available from: https:\/\/www.has-sante.fr\/jcms\/p_3460918\/fr\/strategie-vaccinale-de-prevention-des-infections-par-le-vrs-chez-l-adulte-age-de-60-ans-et-plus"},{"key":"e_1_3_6_11_1","unstructured":"WHO. Vaccines and immunization [Internet]. 2025 [cited 2025 Oct 6]. Available from: https:\/\/www.who.int\/health-topics\/vaccines-and-immunization#tab=tab_1"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-10071-z"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.banm.2024.10.020"},{"key":"e_1_3_6_14_1","unstructured":"Sant\u00e9 publique France. Simplified vaccination schedule [Internet]. 2025. Available from: https:\/\/www.bing.com\/ck\/a?!&&p=01b844764a0b5fdde77c27911f57864c8b99837a3e5da10ca910c951c9958a73JmltdHM9MTc3MTM3MjgwMA&ptn=3&ver=2&hsh=4&fclid=2d2f73e0-dc2b-6d82-3c8b-677cdd526c07&psq=National+immunization+program+france&u=a1aHR0cHM6Ly93d3cuc2FudGVwdWJsaXF1ZWZyYW5jZS5mci9jb250ZW50L2Rvd25sb2FkLzcxOTk1Mi80NjYxOTUxP3ZlcnNpb249MQ"},{"key":"e_1_3_6_15_1","unstructured":"WHO. Immunization Agenda 2030 [Internet]. Immunization Agenda 2030. 2020 [cited 2025 Aug 28]. Available from: https:\/\/www.immunizationagenda2030.org\/"},{"key":"e_1_3_6_16_1","unstructured":"WHO. Global COVID-19 vaccination strategy in a changing world: July 2022 update [Internet]. 2022 [cited 2025 Jul 4]. Available from: https:\/\/www.who.int\/publications\/m\/item\/global-covid-19-vaccination-strategy-in-a-changing-world--july-2022-update"},{"key":"e_1_3_6_17_1","unstructured":"WHO. Managing seasonal vaccination policies and coverage in the European region [Internet]. 2024 [cited 2025 Jul 4]. Available from: https:\/\/www.who.int\/europe\/activities\/managing-seasonal-vaccination-policies-and-coverage-in-the-european-region"},{"key":"e_1_3_6_18_1","unstructured":"Vaccines Europe. \u201c15 years on: updating the EU\u2019s 75% uptake target to manage the triple threat of flu COVID-19 and RSV\u201d 16 October 2024 Brussels (belgium) and online [Internet]. 2024 [cited 2025 Aug 21]. Available from: https:\/\/www.vaccineseurope.eu\/media-hub\/events\/15-years-on-updating-the-eus-75-uptake-target-to-manage-the-triple-threat-of-flu-covid-19-and-rsv-16-october-2024-brussels-belgium-and-online\/"},{"key":"e_1_3_6_19_1","unstructured":"EHMA. EHMA call to action: establishing a European vaccination coverage target for pneumococcal disease in adults [Internet]. EHMA. 2025 [cited 2025 Sep 19]. Available from: https:\/\/ehma.org\/ehma-call-to-action-establishing-a-european-vaccination-coverage-target-for-pneumococcal-disease-in-adults\/"},{"key":"e_1_3_6_20_1","unstructured":"Sant\u00e9 publique France. Infections respiratoires aigu\u00ebs (grippe bronchiolite COVID-19). Bilan de la saison 2024\u20132025 [Internet]. Report No.: semaine 15. 2025. Available from: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-et-infections-respiratoires\/grippe\/documents\/bulletin-national\/infections-respiratoires-aigues-grippe-bronchiolite-covid-19-.-bilan-de-la-saison-2024-2025"},{"key":"e_1_3_6_21_1","unstructured":"Wyplosz B Loubet P Cases A et al. Low pneumococcal vaccination coverage in France: would a vaccination in the 65+ help identifying at-risk population? Barcelona. 2024. Available from: https:\/\/static.hevaweb.com\/web\/PDF\/40c12168b8266-2024-04-24-eccmid-p3836-vf.pdf"},{"key":"e_1_3_6_22_1","unstructured":"Sant\u00e9 publique. Donn\u00e9es de couverture vaccinale grippe par groupe d\u2019\u00e2ge [Internet]. 2025 [cited 2026 Jan 13]. Available from: https:\/\/www.santepubliquefrance.fr\/determinants-de-sante\/vaccination\/donnees-de-couverture-vaccinale-grippe-par-groupe-d-age"},{"key":"e_1_3_6_23_1","unstructured":"Wyplosz B Grenier B Blanc E et al. \u00c9volution des couvertures vaccinales pneumococciques et grippales des adultes \u00e0 risque avant (2019) et apr\u00e8s le COVID (2023). [Internet]. 2025. Available from: ricai.fr."},{"key":"e_1_3_6_24_1","unstructured":"HAS. \u00c9largissement des crit\u00e8res d\u2019\u00e9ligibilit\u00e9 \u00e0 la vaccination antipneumococcique chez les adultes - Recommandation vaccinale [Internet]. Haute Autorit\u00e9 de Sant\u00e9; 2025 [cited 2025 Oct 31]. Available from: https:\/\/www.has-sante.fr\/jcms\/p_3586414\/fr\/elargissement-des-criteres-d-eligibilite-a-la-vaccination-antipneumococcique-chez-les-adultes-recommandation-vaccinale"},{"key":"e_1_3_6_25_1","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de G\u00e9riatrie et G\u00e9rontologie. SUR LES INFECTIONS RESPIRATOIRES \u00c0 PR\u00c9VENTION VACCINALE DES SENIOR. 2025."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4015886"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.018"},{"key":"e_1_3_6_28_1","unstructured":"El Banhawi H Chowdury S Neri M et al. The socioeconomic value of adult immunisation programmes [Internet]. London: Office of Health Economics; 2024. Available from: https:\/\/www.ohe.org\/publications\/the-socio-economic-value-of-adult-immunisation-programmes\/"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2536093"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2536092"},{"issue":"7","key":"e_1_3_6_31_1","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study","volume":"2","author":"Jit M","year":"2014","unstructured":"Jit M, Brisson M, Portnoy A, et al. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2(7):e406\u2013414.","journal-title":"Lancet Glob Health"},{"key":"e_1_3_6_32_1","unstructured":"Le Haut-commissariat \u00e0 la Strat\u00e9gie. L\u2019\u00e9valuation socio\u00e9conomique des investissements publics [Internet]. 2013 [cited 2025 Dec 9]. Available from: https:\/\/www.strategie-plan.gouv.fr\/publications\/levaluation-socioeconomique-investissements-publics-tome1"},{"key":"e_1_3_6_33_1","unstructured":"Ined. Life table - Deaths causes of mortality - France - Data - Ined - Institut national d\u2019\u00e9tudes d\u00e9mographiques [Internet]. 2023 [cited 2025 Oct 31]. Available from: https:\/\/www.ined.fr\/en\/everything_about_population\/data\/france\/deaths-causes-mortality\/mortality-tables\/"},{"key":"e_1_3_6_34_1","unstructured":"OECD. Employment rate by age group [Internet]. OECD; 2025 [cited 2025 Oct 20]. Available from: https:\/\/www.oecd.org\/en\/data\/indicators\/employment-rate-by-age-group.html"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1780847"},{"issue":"1","key":"e_1_3_6_36_1","first-page":"S102","article-title":"Exploratory analysis of the economically justifiable price of a hypothetical RSV vaccine for older adults in the Netherlands and the United Kingdom","volume":"226","author":"Zeevat F","year":"2021","unstructured":"Zeevat F, Luttjeboer J, Paulissen JHJ, et al. Exploratory analysis of the economically justifiable price of a hypothetical RSV vaccine for older adults in the Netherlands and the United Kingdom. J Infect Dis. 2021;226(Suppl 1):S102\u2013S109.","journal-title":"J Infect Dis"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/jmahp12040026"},{"key":"e_1_3_6_38_1","unstructured":"World Bank. World Bank Open Data [Internet]. World Bank Open Data; 2025 [cited 2025 May 6]. Available from: https:\/\/data.worldbank.org\/"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408544"},{"key":"e_1_3_6_40_1","unstructured":"CDC. Pneumococcal Vaccination [Internet]. Pneumococcal Disease. 2025 [cited 2025 Mar 10]. Available from: https:\/\/www.cdc.gov\/pneumococcal\/vaccines\/index.html"},{"key":"e_1_3_6_41_1","unstructured":"CDC. Respiratory syncytial virus (RSV) vaccination coverage and intent for vaccination adults 75 years and older and adults 50\u201374 years with high-risk conditions* United States [Internet]. RSVVaxView. 2025 [cited 2026 Jan 13]. Available from: https:\/\/www.cdc.gov\/rsvvaxview\/dashboard\/adults-50-coverage-intent.html"},{"key":"e_1_3_6_42_1","doi-asserted-by":"crossref","unstructured":"Tartof SY Aliabadi N Zasowski E. Vaccine effectiveness of bivalent RSVpreF against hospitalization or emergency department visits for respiratory syncytial virus-related respiratory illness across two RSV seasons at a large integrated US healthcare network [Internet]. Rochester (NY): Social Science Research Network; 2025 [cited 2026 Apr 15]. Available from: https:\/\/papers.ssrn.com\/abstract=5803145","DOI":"10.2139\/ssrn.5803145"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2436183"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213836"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf061"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2026.31.2.2500992"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70081"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2024-001074"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102995"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0342382"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2576243"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70009"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.05.067"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.10.2400109"},{"key":"e_1_3_6_55_1","unstructured":"Vaccination Info Service. Covid-19 [Internet]. 2025 [cited 2025 Dec 15]. Available from: https:\/\/vaccination-info-service.fr\/Les-maladies-et-leurs-vaccins\/Covid-19"},{"key":"e_1_3_6_56_1","unstructured":"Langedijk AC van den Dungen F de Goeij MHM et al. Cost-effectiveness of bivalent respiratory syncytial virus stabilized prefusion F subunit vaccine (RSVpreF) among older adults in the Netherlands [Internet]. 2026 [cited 2026 Apr 15]. Available from: https:\/\/scientificpubs.congressposter.com\/p\/2d2jiq4vdbpo2cog"},{"key":"e_1_3_6_57_1","unstructured":"CDC. Past seasons\u2019 vaccine effectiveness estimates [Internet]. Flu Vaccines Work. 2024 [cited 2025 May 6]. Available from: https:\/\/www.cdc.gov\/flu-vaccines-work\/php\/effectiveness-studies\/past-seasons-estimates.html"},{"key":"e_1_3_6_58_1","unstructured":"Haut-commissariat \u00e0 la strat\u00e9gie et au plan. L\u2019\u00e9valuation socio\u00e9conomique des investissements publics (Tome 1) | Haut-commissariat \u00e0 la strat\u00e9gie et au plan [Internet]. 2013 [cited 2025 Oct 3]. Available from: https:\/\/www.strategie-plan.gouv.fr\/publications\/levaluation-socioeconomique-investissements-publics-tome1\/"},{"key":"e_1_3_6_59_1","unstructured":"World Bank. World Bank open data [Internet]. World Bank Open Data. 2025 [cited 2025 Dec 11]. Available from: https:\/\/data.worldbank.org"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08078-2"},{"key":"e_1_3_6_61_1","unstructured":"Tunnicliffe E Hayes H O\u2019Neill P et al. Analysing global immunisation expenditure. [Internet]. London: Office of Health Economics; 2025. Available from: https:\/\/www.ohe.org\/publications\/analysing-global-immunisation-expenditure\/"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02282-y"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2024.102513"},{"key":"e_1_3_6_64_1","unstructured":"Didier M Lefebvre G. Health expenditure in 2023 \u2013 Results of the health accounts \u2013 Edition 2024 | Direction de la recherche des \u00e9tudes de l\u2019\u00e9valuation et des statistiques [Internet]. 2025 [cited 2025 Dec 11]. Available from: https:\/\/drees.solidarites-sante.gouv.fr\/publications-en-anglais\/health-expenditure-2023"},{"key":"e_1_3_6_65_1","unstructured":"INED. Projections - evolution of population - France - Data [Internet]. Ined - Institut national d\u2019\u00e9tudes d\u00e9mographiques. 2025 [cited 2025 Oct 6]. Available from: https:\/\/www.ined.fr\/en\/everything_about_population\/data\/france\/population-evolution\/projections\/"},{"key":"e_1_3_6_66_1","unstructured":"Panizzo A. La France championne d\u2019Europe de la d\u00e9pense sociale pour quels r\u00e9sultats? [Internet]. Previssima. 2025 [cited 2026 Mar 20]. Available from: https:\/\/www.previssima.fr\/actualite\/la-france-championne-deurope-de-la-depense-sociale-pour-quels-resultats.html"},{"key":"e_1_3_6_67_1","unstructured":"Politico. France risks running out of cash for social spending auditors say [Internet]. POLITICO; 2025 [cited 2026 Mar 20]. Available from: https:\/\/www.politico.eu\/article\/france-risks-running-out-cash-social-spending-court-auditors-say\/"},{"key":"e_1_3_6_68_1","unstructured":"Cook H. France \u2013 bracing for an autumn budget showdown [Internet]. MUFG Research. 2025 [cited 2025 Oct 6]. Available from: https:\/\/www.mufgresearch.com\/macro\/european-macro-16-july-2025\/"},{"key":"e_1_3_6_69_1","unstructured":"INSEE. At the end of Q2 2025 the Maastricht debt accounted for 115.6% of GDP - Informations rapides - 244 | Insee [Internet]. 2025 [cited 2025 Oct 6]. Available from: https:\/\/www.insee.fr\/en\/statistiques\/8646133"},{"key":"e_1_3_6_70_1","unstructured":"Politico. Macron promises billions more for French defense budget [Internet]. POLITICO. 2025 [cited 2025 Oct 6]. Available from: https:\/\/www.politico.eu\/article\/emmanuel-macron-france-defense-budget\/"},{"key":"e_1_3_6_71_1","doi-asserted-by":"crossref","unstructured":"Boileau B Warner M. UK defence spending: composition commitments and challenges. 2025 [cited 2025 Oct 6]. doi: 10.1920\/re.ifs.2025.0029","DOI":"10.1920\/re.ifs.2025.0029"},{"key":"e_1_3_6_72_1","unstructured":"WHO. Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use: technical report [Internet]. 2024 [cited 2025 Oct 21]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240098787"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf710"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2016.1271997"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41479-023-00110-y"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001211"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9836"},{"key":"e_1_3_6_78_1","unstructured":"Legifrance. D\u00e9cret n\u00b0 2023\u2013736 du 8 ao\u00fbt 2023 relatif aux comp\u00e9tences vaccinales des infirmiers des pharmaciens d\u2019officine des infirmiers et des pharmaciens exer\u00e7ant au sein des pharmacies \u00e0 usage int\u00e9rieur des professionnels de sant\u00e9 exer\u00e7ant au sein des laboratoires de biologie m\u00e9dicale et des \u00e9tudiants en troisi\u00e8me cycle des \u00e9tudes pharmaceutiques - L\u00e9gifrance [Internet]. 2023 [cited 2026 Jun 15]. Available from: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFARTI000047949018"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2704173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14760584.2026.2704173","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2704173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:26:30Z","timestamp":1784719590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2026.2704173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14760584.2026.2704173"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2026.2704173","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2704173"}}